IP Library Granted Patent US 9,447,134
Granted Patent B2
US 9,447,134 · App. 14/421,818 · Granted Sep 20, 2016

Compounds and methods for treating mammalian gastrointestinal microbial infections

Inventors: Lizbeth K. Hedstrom (Newton, MA); Gregory D. Cuny (Houston, TX); Suresh K. Gorla (Gurgaon, IN); Mandapati Kavitha (Gurgaon, IN)
Assignees: Brandeis University; The Brigham and Women's Hospital, Inc.
C07H15/203A61K31/17A61K31/277A61K31/325A61K31/4184A61K31/4192A61K31/423A61K31/427A61K31/44A61K31/4409A61K31/4439A61K31/47A61K31/4709A61K31/496A61K31/502A61K31/5375A61K31/7036A61K45/06C07C271/44C07C271/50C07C271/52C07C275/28C07C275/30C07C275/34C07C275/36C07C275/38C07C275/40C07C275/42C07C381/00C07D213/75C07D215/38C07D237/32C07D249/18C07D263/57C07D295/088C07D295/135C07D319/18C07D401/04C07D401/12C07D405/12C07D413/04C07D413/12C07D413/14C07D417/04C07C2101/02C07C2103/74
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,447,134
App. No.
14/421,818
Granted
Sep 20, 2016
Kind
B2
Abstract

Disclosed are compounds and pharmaceutically acceptable salts thereof, which are useful as inhibitors of IMPDH. In certain embodiments, a compound selectively inhibits a parasitic IMPDH versus a host IMPDH. Also disclosed are pharmaceutical compositions comprising one or more compounds of the invention. Related methods of treating various parasitic and bacterial infections in mammals are disclosed. Moreover, the compounds may be used alone or in combination with other therapeutic or prophylactic agents, such as anti-virals, anti-inflammatory agents, antimicrobials and immunosuppressants.

Claims (38)

1. A compound, or a pharmaceutically acceptable salt or ester thereof, selected from the group consisting of

2. A compound, or a pharmaceutically acceptable salt or ester thereof, represented by Formula X or Formula XIII:

wherein, independently for each occurrence,

X 3 X is C(R′) 2 , S, or NR′;

wherein R′ is hydrogen, halide, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, acyl, aracyl, or heteroaracyl;

m is 0, 1, or 2;

n is 0, 1, 2, or 3;

R 14 X is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, acyl, aracyl, heteroaracyl sulfonate, sulfonyl, sulfonamido, formyl, carboxyl, alkoxycarbonyl, or acyloxy, or two R 14 X groups taken together form a non-aromatic 3-8 membered ring, or two R 14 X groups taken together form the side chain of a natural or non-natural D or L amino acid;

Z X is hydrogen, halo, azido, alkyl, haloalkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, heteroaralkyl, hydroxy, alkoxy, aryloxy, heteroaryloxy, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, acyl, carboxyl, alkoxycarbonyl, acyloxy, silyl, alkylthio, sulfonate, sulfonyl, sulfonamido, sulfhydryl, formyl, cyano, or isocyano;

 is hydrogen, halogen, alkyl, alkenyl, alkynyl, aralkyl, heteroaralkyl, halogen, amino, amido, acyl, aracyl, heteroaracyl, alkoxy, hydroxyl, carboxyl, alkoxylcarbonyl, acyloxy, silyl, alkylthio, sulfonate, sulfonyl, sulfonamido, sulfhydryl, formyl, cyano, isocyano, monocyclic or bicyclic cycloalkyl, monocyclic or bicyclic heterocyclyl, monocyclic or bicyclic aryl or monocyclic or bicyclic heteroaryl; and

 is monocyclic or bicyclic cycloalkyl, monocyclic or bicyclic heterocyclyl, monocyclic or bicyclic aryl or monocyclic or bicyclic heteroaryl;

wherein, independently for each occurrence,

X 3 XIII is absent, O, C(R′) 2 , S, or NR′;

R 14 XIII is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, acyl, aracyl, heteroaracyl sulfonate, sulfonyl, sulfonamido, formyl, carboxyl, alkoxycarbonyl, or acyloxy, or two R 14 XIII groups taken together form a non-aromatic 3-8 membered ring, or two R 14 XIII groups taken together form the side chain of a natural or non-natural D or L amino acid;

Z XIII is halo, azido, alkyl, haloalkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, heteroaralkyl, hydroxy, alkoxy, aryloxy, heteroaryloxy, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, acyl, carboxyl, alkoxycarbonyl, acyloxy, silyl, alkylthio, sulfonate, sulfonyl, sulfonamido, sulfhydryl, formyl, cyano, or isocyano;

 is hydrogen, alkyl, alkenyl, alkynyl, aralkyl, heteroaralkyl, halogen, amino, amido, acyl, aracyl, heteroaracyl, alkoxy, hydroxyl, carboxyl, alkoxylcarbonyl, acyloxy, silyl, alkylthio, sulfonate, sulfonyl, sulfonamido, sulfhydryl, formyl, cyano, isocyano, monocyclic or bicyclic cycloalkyl, monocyclic or bicyclic heterocyclyl, monocyclic or bicyclic aryl or monocyclic or bicyclic heteroaryl;

 is monocyclic or bicyclic cycloalkyl, monocyclic or bicyclic heterocyclyl, or monocyclic or bicyclic heteroaryl;

p is 1, 2, or 3; and

wherein R′ and m are as defined for Formula X;

wherein, any of the aforementioned alkyl, aryl, or heteroaryl may be substituted with one or more groups independently selected from the group consisting of halo, azido, alkyl, haloalkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, heteroaralkyl, hydroxy, alkoxy, aryloxy, heteroaryloxy, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, acyl, carboxyl, alkoxycarbonyl, acyloxy, silyl, alkylthio, sulfonate, sulfonyl, sulfonamido, sulfhydryl, formyl, cyano, and isocyano.

3. A compound or a pharmaceutically acceptable salt or ester thereof, selected from the group consisting of

4. A method of killing or inhibiting the growth of a microbe, comprising the step of contacting said microbe with an effective amount of a compound of claim 1 .

5. The method of claim 4 , wherein said microbe is a protozoan or a bacterium.

6. The method of claim 4 , wherein said microbe is a protozoan or a bacterium selected from the group consisting of the genera Toxoplasma, Eimeria, Cryptosporidium, Plasmodium, Babesia, Theileria, Neospora, Sarcocystis, Giardia, Entamoeba, Tritrichomonas, Leishmania, Trypanosoma, Helicobacter, Borrelia, Salmonella, Shigella, Yersinia, Streptococcus, Campylobacter, Arcobacter, Bacteroides, Fusobacterium, Burkholderia, Clostridia, Neisseria, Mycobacterium , and Acinetobacter.

7. The method of claim 5 , wherein said microbe is a protozoan; and said protozoan is selected from the group consisting of the genera Cryptosporidium, Entamoeba, Leishmania and Trypanosoma.

8. The method of claim 7 , wherein said protozoan is selected from the genus Cryptosporidium.

9. The method of claim 5 , wherein said microbe is a bacterium; and said bacterium is selected from the group consisting of the genera Acinetobacter, Arcobacter, Bacillus, Bacteroides, Borrelia, Brachyspira, Brucella, Burkholderia, Campylobacter, Clostridia, Coxiella, Enterococcus, Erysipelothrix, Francisella, Fusobacterium, Helicobacter, Lactobacillus, Listeria, Mycobacterium, Neisseria, Pseudomonas, Staphylococcus and Streptococcus.

10. A method of treating or preventing a microbial infection in a mammal or bird comprising the step of administering to a mammal or bird in need thereof a therapeutically effective amount of a compound of claim 1 .

11. The method of claim 10 , wherein said microbial infection is caused by a protozoan or bacterium.

12. The method of claim 10 , wherein said microbial infection is caused by a protozoan or a bacterium selected from the group consisting of the genera Cryptosporidium, Entamoeba, Leishmania, Trypanosoma, Acinetobacter, Arcobacter, Bacillus, Bacteroides, Borrelia, Brachyspira, Brucella, Burkholderia, Campylobacter, Clostridia, Coxiella, Enterococcus, Erysipelothrix, Francisella, Fusobacterium, Helicobacter, Lactobacillus, Listeria, Mycobacterium, Neisseria, Pseudomonas, Staphylococcus and Streptococcus.

13. The method of claim 11 , wherein said microbial infection is caused by a protozoan; and said protozoan is selected from the group consisting of the genera Cryptosporidium, Entamoeba, Leishmania and Trypanosoma.

14. The method of claim 13 , wherein said protozoan is selected from the genus Cryptosporidium.

15. The method of claim 11 , wherein said microbial infection is caused by a bacterium; and said bacterium is selected from the group consisting of the genera Acinetobacter, Arcobacter, Bacillus, Bacteroides, Borrelia, Brachyspira, Brucella, Burkholderia, Campylobacter, Clostridia, Coxiella, Enterococcus, Erysipelothrix, Francisella, Fusobacterium, Helicobacter, Lactobacillus, Listeria, Mycobacterium, Neisseria, Pseudomonas, Staphylococcus and Streptococcus.

16. The method of claim 10 , further comprising the step of co-administering to a mammal or bird in need thereof a therapeutically effective amount of an antimicrobial agent.

17. The method of claim 16 , wherein said antimicrobial agent is an antibiotic.

18. The method of claim 16 , wherein said antimicrobial agent is an antiparasitic.

19. The method of claim 10 , wherein said infection is in a mammal; and the mammal is a primate, a bovine, an ovine, an equine, a porcine, a rodent, a feline, a mustelid, or a canine.

20. The method of claim 10 , wherein said infection is in a mammal; and the mammal is a human.

Assignments (3)
CONFIRMATORY LICENSE Recorded Dec 15, 2017
From: BRANDEIS UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 044882/0245 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 19, 2015
From: CUNY, GREGORY D.
To: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
Reel/Frame 035201/0602 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 19, 2015
From: HEDSTROM, LIZBETH K.; GORLA, SURESH KUMAR; KAVITHA, MANDAPATI
To: BRANDEIS UNIVERSITY
Reel/Frame 035201/0607 →
Continuity (2)
Provisional Application 61684263 · Aug 17, 2012
Related Publication 20150210727A1 · Jul 30, 2015